Emerging therapies for treatment of agitation, psychosis, or apathy in Alzheimer's disease.
Expert Opin Emerg Drugs
; 29(3): 289-303, 2024 Sep.
Article
en En
| MEDLINE
| ID: mdl-38822731
ABSTRACT
INTRODUCTION:
Agitation, psychosis, and apathy are prevalent and highly distressing neuropsychiatric symptoms (NPS) of Alzheimer's disease (AD) that have been linked to numerous negative outcomes, including increased mortality, worsened cognitive decline, and caregiver burden. Current treatments for AD-associated agitation, namely atypical antipsychotics, provide some benefits but may increase the risk of serious adverse events and death. Meanwhile, no pharmacotherapies have been approved by regulatory agencies for the treatment of psychosis or apathy in AD. Over the past decade, many new and repurposed drugs have emerged as potential therapeutic options for managing these challenging NPS. AREAS COVERED This review aims to provide a comprehensive summary of pharmacotherapies that have recently been investigated in phase 2 and 3 clinical trials for the treatment of agitation, psychosis, or apathy in AD. EXPERT OPINION Novel atypical antipsychotics, serotonergic antidepressants, cannabinoids, and dextromethorphan combination drugs have shown promising results for alleviating agitation. Pimavanserin appears to be the most effective emerging therapy for psychosis, while methylphenidate has demonstrated good efficacy for apathy. Further research on biomarkers of NPS severity and treatment response, as well as continued improvements in methodological approaches are needed to advance the field.Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Agitación Psicomotora
/
Trastornos Psicóticos
/
Antipsicóticos
/
Apatía
/
Enfermedad de Alzheimer
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Expert Opin Emerg Drugs
/
Expert opin. emerg. drugs (Online)
/
Expert opinion on emerging drugs (Online)
Asunto de la revista:
TERAPIA POR MEDICAMENTOS
Año:
2024
Tipo del documento:
Article
País de afiliación:
Canadá